11.27

2.59% -0.30

After Hours: 11.23 -0.04 -0.35%

Promis Neurosciences Inc (PMN)

Overview News Price History Financials Discussions Forecast Stock Split

Promis Neurosciences Inc stock is traded at $11.27, with a volume of 20,104. It is down -2.59% in the last 24 hours and down -26.63% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Previous Close:

$11.57

Open:

$12.06

24h Volume:

20,104

Relative Volume:

0.23

Market Cap:

$101.07M

Revenue:

Net Income/Loss:

$-40.62M

P/E Ratio:

-0.5807

EPS:

-19.4076

Net Cash Flow:

$-35.63M

1W Performance:

-19.56%

1M Performance:

-26.63%

6M Performance:

-28.90%

1Y Performance:

+12.98%

1-Day Range:

$11.15

$12.06

1-Week Range:

$11.15

$14.22

52-Week Range:

$6.27

$27.40

Promis Neurosciences Inc Stock (PMN) Company Profile

Name

Promis Neurosciences Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

416-847-6898

Address

SUITE 200, 1920 YONGE STREET, TORONTO

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

PMN's Discussions on Twitter

Compare PMN vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PMN Promis Neurosciences Inc	11.27	101.07M	0	-40.62M	-35.63M	-19.41
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Promis Neurosciences Inc Stock (PMN) Latest News

Sep 20, 2026

ProMIS Neurosciences, Inc.(NasdaqCM: PMN) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Sep 17, 2026

PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade

Sep 17, 2026

Sep 15, 2026

ProMIS Neurosciences at H.C. Wainwright conference: safety stands out By Investing.com - Investing.com Canada

Sep 15, 2026

Sep 14, 2026

ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - kalkine.com.au

Sep 14, 2026

Sep 10, 2026

ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com - Investing.com Canada

Sep 10, 2026

Sep 09, 2026

ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Nigeria

Sep 09, 2026

ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus - Investing.com India

Sep 09, 2026

ProMIS Neurosciences (PMN) Edges Up 0.24% to $12.56 as Shares Consolidate Between Support and ResistanceChannel Breakout - siam.in

Sep 09, 2026

Sep 04, 2026